Next-generation cell and gene therapies are driving a logistics overhaul because supply chains must protect living, patient-specific products through extremely tight stability windows. The operational requirements extend beyond shipping—packaging validation, cold-chain integrity, and coordination with clinical scheduling are now core determinants of whether a therapy actually reaches dosing-ready status. Industry coverage highlights that in some CGT pathways, delivery windows may be as short as 30 minutes due to cell viability constraints and preconditioning timing. When shipments fail, patients can face delays that cascade into repeat procedures and the need to recreate bespoke starting materials and manufacturing batches. The underlying message: standard pharmaceutical freight and monitoring approaches are increasingly insufficient for CGT, elevating specialized logistics providers, real-time visibility into critical data, and rapid contingency execution to risk-management essentials.